A single dose treatment to assess nerve damage after injury
A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma
This study is testing a new way to quickly find out if a damaged nerve is completely cut or just hurt, using a single dose of a special drug, so that doctors can make faster treatment decisions for people with nerve injuries.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-10929481 on NIH RePORTER |
What this research studies
This research investigates a new diagnostic approach to determine the continuity of peripheral nerves after traumatic injuries. By using a single dose of a specific drug, the study aims to provide immediate insights into whether a nerve is severed or merely damaged, which is crucial for deciding the appropriate treatment. Currently, doctors must wait weeks to assess nerve injuries, leading to potential delays in necessary surgical interventions. This innovative method could significantly improve the speed and accuracy of nerve injury diagnosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced traumatic peripheral nerve injuries from various causes, including accidents or surgical complications.
Not a fit: Patients with non-traumatic nerve injuries or those whose nerve damage is chronic and unrelated to recent trauma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster and more accurate treatment decisions for patients with nerve injuries, potentially improving recovery outcomes.
How similar studies have performed: While the approach is innovative, similar diagnostic methods in other tissue types have shown success, suggesting potential for this novel application in nerve injury assessment.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Elfar, John — University of Arizona
- Study coordinator: Elfar, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.